PMID- 33287318
OWN - NLM
STAT- MEDLINE
DCOM- 20210406
LR  - 20210406
IS  - 1420-3049 (Electronic)
IS  - 1420-3049 (Linking)
VI  - 25
IP  - 23
DP  - 2020 Dec 3
TI  - Bioactive Agent Discovery from the Natural Compounds for the Treatment of Type 2 
      Diabetes Rat Model.
LID - 10.3390/molecules25235713 [doi]
LID - 5713
AB  - Diabetes mellitus is a well-known chronic metabolic disease that poses a 
      long-term threat to human health and is characterized by a relative or absolute 
      lack of insulin, resulting in hyperglycemia. Type 2 diabetes mellitus (T2DM) 
      typically affects many metabolic pathways, resulting in beta-cell dysfunction, 
      insulin resistance, abnormal blood glucose levels, inflammatory processes, 
      excessive oxidative reactions, and impaired lipid metabolism. It also leads to 
      diabetes-related complications in many organ systems. Antidiabetic drugs have 
      been approved for the treatment of hyperglycemia in T2DM; these are beneficial 
      for glucose metabolism and promote weight loss, but have the risk of side 
      effects, such as nausea or an upset stomach. A wide range of active components, 
      derived from medicinal plants, such as alkaloids, flavonoids, polyphenol, 
      quinones, and terpenoids may act as alternative sources of antidiabetic agents. 
      They are usually attributed to improvements in pancreatic function by increasing 
      insulin secretions or by reducing the intestinal absorption of glucose. Ease of 
      availability, low cost, least undesirable side effects, and powerful 
      pharmacological actions make plant-based preparations the key player of all 
      available treatments. Based on the study of therapeutic reagents in the 
      pathogenesis of humans, we use the appropriate animal models of T2DM to evaluate 
      medicinal plant treatments. Many of the rat models have characteristics similar 
      to those in humans and have the advantages of ease of genetic manipulation, a 
      short breeding span, and access to physiological and invasive testing. In this 
      review, we summarize the pathophysiological status of T2DM rat models and focus 
      on several bioactive compounds from herbal medicine with different functional 
      groups that exhibit therapeutic potential in the T2DM rat models, in turn, may 
      guide future approach in treating diabetes with natural drugs.
FAU - Yang, Shih-Chun
AU  - Yang SC
AD  - Department of Cosmetic Science, Providence University, Taichung 43301, Taiwan.
FAU - Hsu, Ching-Yun
AU  - Hsu CY
AD  - Department of Nutrition and Health Sciences, Chang Gung University of Science and 
      Technology, Kweishan, Taoyuan 33303, Taiwan.
AD  - Research Center for Food and Cosmetic Safety, Chang Gung University of Science 
      and Technology, Kweishan, Taoyuan 33303, Taiwan.
AD  - Research Center for Chinese Herbal Medicine, Chang Gung University of Science and 
      Technology, Kweishan, Taoyuan 33303, Taiwan.
FAU - Chou, Wei-Ling
AU  - Chou WL
AD  - Department of Traditional Chinese Medicine, Chang Gung Memorial Hospital, Keelung 
      20401, Taiwan.
FAU - Fang, Jia-You
AU  - Fang JY
AUID- ORCID: 0000-0003-2114-7709
AD  - Research Center for Food and Cosmetic Safety, Chang Gung University of Science 
      and Technology, Kweishan, Taoyuan 33303, Taiwan.
AD  - Research Center for Chinese Herbal Medicine, Chang Gung University of Science and 
      Technology, Kweishan, Taoyuan 33303, Taiwan.
AD  - Pharmaceutics Laboratory, Graduate Institute of Natural Products, Chang Gung 
      University, Kweishan, Taoyuan 33303, Taiwan.
AD  - Department of Anesthesiology, Chang Gung Memorial Hospital, Kweishan, Taoyuan 
      33303, Taiwan.
FAU - Chuang, Shih-Yi
AU  - Chuang SY
AD  - Pharmaceutics Laboratory, Graduate Institute of Natural Products, Chang Gung 
      University, Kweishan, Taoyuan 33303, Taiwan.
LA  - eng
GR  - CMRPD1K0051-2/Chang Gung Memorial Hospital/
GR  - CMRPD1F0331-3/Chang Gung Memorial Hospital/
PT  - Journal Article
PT  - Review
DEP - 20201203
PL  - Switzerland
TA  - Molecules
JT  - Molecules (Basel, Switzerland)
JID - 100964009
RN  - 0 (Biological Products)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Phytochemicals)
SB  - IM
MH  - Animals
MH  - Biological Products/*pharmacology/*therapeutic use
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Disease Models, Animal
MH  - Humans
MH  - Hyperglycemia/drug therapy
MH  - Hypoglycemic Agents/*pharmacology/*therapeutic use
MH  - Phytochemicals/pharmacology/therapeutic use
MH  - Plants, Medicinal/chemistry
MH  - Rats
PMC - PMC7731446
OTO - NOTNLM
OT  - Type 2 diabetes mellitus
OT  - animal model
OT  - drug development
OT  - herbal medicine
OT  - insulin resistance
COIS- The authors report no conflicts of interest in this work.
EDAT- 2020/12/09 06:00
MHDA- 2021/04/07 06:00
PMCR- 2020/12/03
CRDT- 2020/12/08 01:07
PHST- 2020/10/13 00:00 [received]
PHST- 2020/11/27 00:00 [revised]
PHST- 2020/11/27 00:00 [accepted]
PHST- 2020/12/08 01:07 [entrez]
PHST- 2020/12/09 06:00 [pubmed]
PHST- 2021/04/07 06:00 [medline]
PHST- 2020/12/03 00:00 [pmc-release]
AID - molecules25235713 [pii]
AID - molecules-25-05713 [pii]
AID - 10.3390/molecules25235713 [doi]
PST - epublish
SO  - Molecules. 2020 Dec 3;25(23):5713. doi: 10.3390/molecules25235713.